|

VAL-413 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Orotecan®

Pipeline

Phase 1: 1

Top Sponsors

  • Valent Technologies, LLC1

Indications

  • Hepatoblastoma1
  • Neuroblastoma1
  • Solid Tumors1
  • Medulloblastoma1
  • Rhabdomyosarcoma1

San Francisco, California1 trial

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

UCSF, Mission Bay - Benioff Children's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.